Arthrosamid is a polyacrylamide hydrogel developed by Contura International Ltd. as a long-lasting intra-articular injection, approved in Europe to treat knee osteoarthritis (OA). The treatment has the potential to change the present care pathway for managing OA, which affects around 8,6 million people in Italy¹…current treatments are not long-lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of OA treatments on offer to help patients – until now.